drugset / Trial / NCT07079540

The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis

NCT07079540

Phase 3 Completed 380 enrolled Jiangsu Sinorda Biomedicine Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of X842 Capsules 50 mg compared to Lansoprazole Enteric Capsules for the treatment of reflux esophagitis, and to characterize the population pharmacokinetics of X842 capsules in this patient population.

Timeline

Start
2021-06-24
Primary completion
2022-07-27
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lansoprazole Other / unclassified 30 mg Oral
Subject Linaprazan glurate Small molecule 50 mg Oral

Indications